These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 28885972

  • 1. Use of Rifapentine and Isoniazid Directly Observed Therapy for the Treatment of Latent Tuberculosis Infection in a Military Clinic.
    Jinbo J, Lustik M, West GF, Kloetzel M.
    Mil Med; 2017 Sep; 182(9):e2024-e2029. PubMed ID: 28885972
    [Abstract] [Full Text] [Related]

  • 2. Improving Treatment Completion Rates for Latent Tuberculosis Infection: A Review of Two Treatment Regimens at a Community Health Center.
    Lines G, Hunter P, Bleything S.
    J Health Care Poor Underserved; 2015 Nov; 26(4):1428-39. PubMed ID: 26548690
    [Abstract] [Full Text] [Related]

  • 3. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
    Arguello Perez E, Seo SK, Schneider WJ, Eisenstein C, Brown AE.
    Clin Infect Dis; 2017 Nov 29; 65(12):2105-2111. PubMed ID: 29020308
    [Abstract] [Full Text] [Related]

  • 4. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study.
    Lam CK, McGinnis Pilote K, Haque A, Burzynski J, Chuck C, Macaraig M.
    J Med Internet Res; 2018 Nov 20; 20(11):e287. PubMed ID: 30459146
    [Abstract] [Full Text] [Related]

  • 5. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons.
    Schmit KM, Lobato MN, Lang SG, Wheeler S, Kendig NE, Bur S.
    J Public Health Manag Pract; 2019 Nov 20; 25(2):E1-E6. PubMed ID: 30024493
    [Abstract] [Full Text] [Related]

  • 6. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
    Simkins J, Abbo LM, Camargo JF, Rosa R, Morris MI.
    Transplantation; 2017 Jun 20; 101(6):1468-1472. PubMed ID: 27548035
    [Abstract] [Full Text] [Related]

  • 7. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2011 Dec 09; 60(48):1650-3. PubMed ID: 22157884
    [Abstract] [Full Text] [Related]

  • 8. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
    McClintock AH, Eastment M, McKinney CM, Pitney CL, Narita M, Park DR, Dhanireddy S, Molnar A.
    BMC Infect Dis; 2017 Feb 14; 17(1):146. PubMed ID: 28196479
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.
    Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, Skidmore B, Moher D, Alvarez GG.
    BMC Infect Dis; 2017 Apr 11; 17(1):265. PubMed ID: 28399802
    [Abstract] [Full Text] [Related]

  • 10. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
    Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, Skidmore B, Alvarez GG.
    Pharmacoepidemiol Drug Saf; 2018 Jun 11; 27(6):557-566. PubMed ID: 29573031
    [Abstract] [Full Text] [Related]

  • 11. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
    Knoll BM, Nog R, Wu Y, Dhand A.
    Infection; 2017 Jun 11; 45(3):335-339. PubMed ID: 28276008
    [Abstract] [Full Text] [Related]

  • 12. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates.
    de Castilla DL, Rakita RM, Spitters CE, Narita M, Jain R, Limaye AP.
    Transplantation; 2014 Jan 27; 97(2):206-11. PubMed ID: 24142036
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE, Bass S, Srinivas P, Miranda C, Johnson L, Pallotta AM.
    Ann Pharmacother; 2020 May 27; 54(5):457-463. PubMed ID: 31729245
    [Abstract] [Full Text] [Related]

  • 14. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW, Yang SF, Yeh YP, Tsao TC, Tsao SM.
    Medicine (Baltimore); 2016 Aug 27; 95(34):e4126. PubMed ID: 27559940
    [Abstract] [Full Text] [Related]

  • 15. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
    Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, Yelk Woodruff R, Allen L, LoBue P, Vernon A.
    MMWR Morb Mortal Wkly Rep; 2018 Jun 29; 67(25):723-726. PubMed ID: 29953429
    [Abstract] [Full Text] [Related]

  • 16. Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics.
    Stennis NL, Burzynski JN, Herbert C, Nilsen D, Macaraig M.
    Clin Infect Dis; 2016 Jan 01; 62(1):53-59. PubMed ID: 26338781
    [Abstract] [Full Text] [Related]

  • 17. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J, Stagg HR, Yates TA, Lipman M, White PJ, Charlett A, Muñoz L, Gosce L, Rangaka MX, Francis M, Hack V, Kunst H, Abubakar I.
    BMC Infect Dis; 2021 Jan 21; 21(1):90. PubMed ID: 33478428
    [Abstract] [Full Text] [Related]

  • 18. Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.
    Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov AS.
    Am J Prev Med; 2018 Aug 21; 55(2):244-252. PubMed ID: 29910114
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN, Fox GJ, Meehan MT, Scott N, Ragonnet R, Viney K, Trauer JM, McBryde ES.
    J Antimicrob Chemother; 2019 Jan 01; 74(1):218-227. PubMed ID: 30295760
    [Abstract] [Full Text] [Related]

  • 20. Updates in the Treatment of Active and Latent Tuberculosis.
    Haas MK, Belknap RW.
    Semin Respir Crit Care Med; 2018 Jun 01; 39(3):297-309. PubMed ID: 30071545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.